Identification

Name
Homatropine
Accession Number
DB11181
Type
Small Molecule
Groups
Approved
Description

Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. Homatropine is included in subtherapeutic amounts as homatropine methylbromide to discourage deliberate overdosage. Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA to be safe and effective.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Homatropine hydrobromideBEW7469QZ051-56-9DWSGTFTVBLXELC-RDYJJYPNSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Isopto Homatropine 2%Liquid2 %OphthalmicAlcon, Inc.1951-12-312016-04-14Canada
Isopto Homatropine 5%Liquid5 %OphthalmicAlcon, Inc.1951-12-312016-03-03Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minims Homatropine Hydrobromide 2%Liquid2 %OphthalmicChauvin Pharmaceuticals Limited1995-12-312003-07-08Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
HomatropineHomatropine hydrobromide (50 mg/5mL)Solution / dropsOphthalmicHub Pharmaceuticals2012-06-102016-02-20Us
Homatropine HydrobromideHomatropine hydrobromide (50 mg/mL)SolutionOphthalmicO Cu Soft, Inc.2014-02-10Not applicableUs
Homatropine Hydrobromide OphthalmicHomatropine hydrobromide (50 mg/mL)SolutionOphthalmicAltaire Pharmaceuticals Inc.2013-05-16Not applicableUs
Categories
UNII
8QS6WCL55Z
CAS number
87-00-3
Weight
Average: 275.348
Monoisotopic: 275.15214354
Chemical Formula
C16H21NO3
InChI Key
ZTVIKZXZYLEVOL-MCOXGKPRSA-N
InChI
InChI=1S/C16H21NO3/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11/h2-6,12-15,18H,7-10H2,1H3/t12-,13+,14+,15?
IUPAC Name
(1R,3S,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2-phenylacetate
SMILES
[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)N2C

Pharmacology

Indication

Indicated as an overdose-rescuing agent in combination with hydrocodone antitussive [Label].

Indicated for the induction of mydriasis in ophthalmic solutions.

Pharmacodynamics

Homatropine is an anticholinergic drug that produces typical anticholinergic effects inducing mydriasis and cycloplegia. Other effects of structurally-related atropine that could also apply to homatropine include inhibition of secretions, tachycardia, relaxation of smooth muscle and central nervous effects including excitation [1].

Mechanism of action

Homatropine is a competitive muscarinic receptor antagonist with a bulky aromatic group in place of the acetyl group of acetylcholine. It is expected to act in similar manner as atropine, producing similar parasympatholytic effects. By blocking muscarinic receptors and cholinergic signalling pathways, homatropine blocks the response of the iris sphincter muscle and cause the pupil to become unresponsive to light upon dilation or mydriasis. It also blocks the accommodative muscle of the ciliary body to cholinergic stimulation [1].

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
AMuscarinic acetylcholine receptor M3
antagonist
Human
AMuscarinic acetylcholine receptor M4
antagonist
Human
AMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

No pharmacokinetic data available.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

No pharmacokinetic data available.

Route of elimination

No pharmacokinetic data available.

Half life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Toxicity

Acute oral LD50 is 1200 mg/kg in rat, 1400 mg/kg in mouse, and 1000 mg/kg in guinea pig [MSDS]. Systemic toxicity may occur following topical overdose of structurally-related ophthalmic atropine, particularly in children. It is characterized by flushing and dryness of the skin, blurred vision, a rapid and irregular pulse, fever, convulsions and hallucinations, and the loss of neuromuscular coordination. Abdominal distension may be observed with infants. Severe intoxication is manifested by central nervous system depression, coma, circulatory and respiratory failure, and death [Label]. Symptomatic and supportive treatment should be initiated. In case of accidental use or overdose in infants and small children, the body surface should be kept moist [Label].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Homatropine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumHomatropine may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Homatropine.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Homatropine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Homatropine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Homatropine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Homatropine.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Homatropine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Homatropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Homatropine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Homatropine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Homatropine.Approved
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Homatropine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Homatropine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Homatropine.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Homatropine.Experimental
Botulinum Toxin Type AHomatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BHomatropine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Homatropine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Homatropine.Approved, Investigational, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Homatropine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Homatropine.Approved
CimetropiumHomatropine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Homatropine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Homatropine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Homatropine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Homatropine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Homatropine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Homatropine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Homatropine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dihydromorphine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Homatropine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Homatropine is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Homatropine can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Homatropine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Homatropine is combined with DPDPE.Experimental
DronabinolHomatropine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Homatropine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Homatropine can be decreased when used in combination with Edrophonium.Approved
EluxadolineHomatropine may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Homatropine.Experimental
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Homatropine.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Homatropine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Homatropine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Homatropine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Homatropine.Approved
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Homatropine.Approved
GalantamineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Homatropine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Homatropine.Approved
Ginkgo bilobaThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.Approved
GlycopyrroniumHomatropine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Homatropine is combined with Heroin.Approved, Illicit, Investigational
Human secretinThe therapeutic efficacy of Human secretin can be decreased when used in combination with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Homatropine can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Homatropine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Homatropine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Homatropine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Homatropine.Approved
IpidacrineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.Approved
IsoflurophateThe therapeutic efficacy of Homatropine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Homatropine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Homatropine is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Homatropine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Homatropine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Homatropine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.Approved, Investigational
MefloquineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Mefloquine.Approved, Investigational
MemantineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Homatropine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Homatropine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Homatropine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Homatropine.Approved, Investigational
MethscopolamineThe risk or severity of adverse effects can be increased when Homatropine is combined with Methscopolamine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Homatropine.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Homatropine is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Homatropine.Approved
MetoclopramideThe therapeutic efficacy of Homatropine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Homatropine.Approved
MianserinMianserin may increase the anticholinergic activities of Homatropine.Approved, Investigational
MinaprineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Homatropine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.Approved, Investigational
NabiloneHomatropine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Homatropine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Homatropine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Homatropine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Homatropine.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Homatropine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Homatropine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.Approved
ParaoxonThe therapeutic efficacy of Homatropine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Homatropine.Approved
PethidineThe risk or severity of adverse effects can be increased when Homatropine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Homatropine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Homatropine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Homatropine is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Physostigmine.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Homatropine is combined with Piritramide.Approved, Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Homatropine.Approved
Potassium ChlorideHomatropine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Homatropine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Homatropine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Homatropine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Homatropine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Homatropine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Homatropine.Approved, Investigational
RamosetronHomatropine may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.Approved, Investigational
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Homatropine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.Approved, Investigational
SulpirideHomatropine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TacrineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Homatropine is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tilidine.Experimental
TiotropiumHomatropine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Homatropine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Homatropine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Homatropine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Homatropine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Homatropine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Homatropine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Homatropine.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Homatropine.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Homatropine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Homatropine.Approved
TyrothricinThe therapeutic efficacy of Homatropine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumHomatropine may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.Approved
Food Interactions
Not Available

References

General References
  1. 13. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 159-161). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
KEGG Compound
C07814
PubChem Substance
347911146
ChemSpider
16498795
ChEBI
5747
ChEMBL
CHEMBL1618018
Wikipedia
Homatropine
ATC Codes
S01FA05 — Homatropine
FDA label
Download (88 KB)
MSDS
Download (47.3 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic50 mg/5mL
SolutionOphthalmic50 mg/mL
LiquidOphthalmic5 %
LiquidOphthalmic2 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)191°C as methylbromide and 212°C as hydrobromideMSDS
water solubilitySoluble as hydrobromideMSDS
Predicted Properties
PropertyValueSource
Water Solubility5.57 mg/mLALOGPS
logP1.91ALOGPS
logP1.59ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)11.99ChemAxon
pKa (Strongest Basic)9.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity75.81 m3·mol-1ChemAxon
Polarizability29.79 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Sim MK, Manjeet S: Muscarinic receptors in the aortae of normo- and hypertensive rats: a binding study. Clin Exp Hypertens. 1993 Mar;15(2):409-21. [PubMed:8467326]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Sim MK, Manjeet S: Muscarinic receptors in the aortae of normo- and hypertensive rats: a binding study. Clin Exp Hypertens. 1993 Mar;15(2):409-21. [PubMed:8467326]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Sim MK, Manjeet S: Muscarinic receptors in the aortae of normo- and hypertensive rats: a binding study. Clin Exp Hypertens. 1993 Mar;15(2):409-21. [PubMed:8467326]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Sim MK, Manjeet S: Muscarinic receptors in the aortae of normo- and hypertensive rats: a binding study. Clin Exp Hypertens. 1993 Mar;15(2):409-21. [PubMed:8467326]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Sim MK, Manjeet S: Muscarinic receptors in the aortae of normo- and hypertensive rats: a binding study. Clin Exp Hypertens. 1993 Mar;15(2):409-21. [PubMed:8467326]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Bencharit S, Morton CL, Xue Y, Potter PM, Redinbo MR: Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol. 2003 May;10(5):349-56. [PubMed:12679808]

Drug created on December 03, 2015 09:51 / Updated on July 02, 2018 20:47